SLC5A2 and heart failure: As a result, we recommend a large, multicenter, and long-term follow-up study involving the combination of spironolactone and the mainstay drug classes in heart failure treatment, such as SGLT2, ARNI, and beta-blockers, including those patients with a preserved ejection fraction, to determine whether these classes of drugs are effective in reducing galectin-3 levels.